Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ancile Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Ancile Pharmaceuticals believes the time is right to profit from botanicals. The FDA has recently shown a willingness to work with companies attempting to develop herbal drugs, while consumer demand for herbal dietary supplements is mushrooming. From botanicals, Ancile plans to develop patentable, proprietary ingredients that have multiple uses, and sell products based on those ingredients in the medical foods, dietary supplement and drug markets.
Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090130

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel